Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax H1N1 VLP Vaccine in Healthy Adults
NCT01072799Phase 2Completed
- Sponsor
- Novavax
- Start
- Oct 2009
- Primary completion
- Mar 2012
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 2009 H1N1 influenza VLP vaccine in influenza A H1N1 infection (H1N1) (4 arms), sponsored by Novavax. Primary endpoint: Safety and tolerability of two injections of A (H1N1) 2009 influenza VLP vaccine at 35 days. Started Oct 2009; status: completed.
02
Drugs
2009 H1N1 influenza VLP vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01072799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01072799.